NCT03851146: A Study of Anti-Lewis Y Chimeric Antigen Receptor-T Cells (LeY-CAR-T) in Patients With Solid Tumours

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: LeY
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 1
Drug Category: Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Tumor must be positive for LeY expression
Exclusions: Patients with active, untreated, unstable central nervous system (CNS) involvement by malignancy- see trial for details; Patients with prior CAR T-cell therapy

Comments are closed.

Up ↑